Qualification of Drivers; Exemption Applications; Epilepsy and Seizure Disorders, 5274-5275 [2020-01551]
Download as PDF
lotter on DSKBCFDHB2PROD with NOTICES
5274
Federal Register / Vol. 85, No. 19 / Wednesday, January 29, 2020 / Notices
Daryl A. Lee (IN)
Trey K. Legg (NE)
Sabah K. Noori (NY)
Dale K. Norris (MN)
Larry M. Pratt (WI)
Rodney J. Redmon (FL)
Todd M. Roth (IN)
Kenneth W. Schmidt (PA)
Keith L. Spence (CT)
Latonia B. Spicer (NC)
Ronald E. Sutton (VA)
Larry M. Tabish (MT)
Forrest K. Williams (MO)
The following seven applicants did
not have 3 years of recent experience
driving a CMV on public highways with
their vision deficiencies:
Lawrence A. DiVetro (NV)
Madeline C. Duran (NM)
Jack M. Elliott (KS)
Johnnie R. Johnson (OK)
William C. Kelley (WI)
Jon A. Stevens (MN)
Trent C. Tonner (IN)
The following seven applicants did
not have sufficient driving experience
over the past 3 years under normal
highway operating conditions (gaps in
driving record):
Alfredo E. Carrillo Posada (CO)
Gregory B. Gosha (AL)
Kelvin A. Hulett (MS)
Leon J. Kirksey (MD)
Jerred R. Murray (NY)
Thomas A. Paukowits (MI)
Rogelio Rocha Monjaraz (MD)
The following applicant was charged
with moving violations in conjunction
with CMV accidents:
Michael W. Leverett (MI)
The following applicant had his
commercial driver’s license suspended
during the 3-year period in relation to
a moving violation:
Thomas M. Bakeberg (SD)
The following applicant contributed
to accident(s) in which the applicant
was operating a CMV, which is a
disqualifying offense:
Bruce E. Hemmer (WI)
The following two applicants did not
hold a license which allowed operation
of vehicles over 26,000 lbs. for all or
part of the 3-year period:
Norman D. Mosley (NJ); and Robert L.
Strange (NC)
The following 13 applicants were
denied for multiple reasons:
Gema L. Alvarado (UT)
Eduardo Arguelles (TX)
John N. Azzopardi (MT)
Frank L. Crenshaw (OH)
Tommie L. Dailey (AL)
Giovanni Gualdron (NJ)
Monica M. Hernandez (CA)
Roman I. Hrabovskyi (NJ)
VerDate Sep<11>2014
17:27 Jan 28, 2020
Jkt 250001
Johnny M. Kruprzak (OH)
Elvin E. Martin (PA)
Kevin D. Melvin (NY)
Michael C. Shelp (NY)
Raymond F. Sitter (ND)
The following two applicants have
not had stable vision for the preceding
3-year period:
William C. Hurtgen (WI); and
James N. Robbins (FL)
The following applicant does not
meet the vision standard in his better
eye:
Keith D. Smith (FL)
The following nine applicants drove
interstate while restricted to intrastate
driving:
Norlan A. Acosta (MD)
Adam J. Crull (WA)
Trina L. Garcia (CA)
Jureco M. Hall (MD)
Nathan J. Plumley (NY)
Izone W. Pulley (MD)
Sonya Rankins (CA)
Arthur L. Spaventa (PA)
Marlon A. Wilson (CT)
Issued on: January 16, 2020.
Larry W. Minor,
Associate Administrator for Policy.
[FR Doc. 2020–01549 Filed 1–28–20; 8:45 am]
BILLING CODE 4910–EX–P
DEPARTMENT OF TRANSPORTATION
Federal Motor Carrier Safety
Administration
[Docket No. FMCSA–2015–0118]
Qualification of Drivers; Exemption
Applications; Epilepsy and Seizure
Disorders
Federal Motor Carrier Safety
Administration (FMCSA), DOT.
ACTION: Notice of final disposition.
AGENCY:
FMCSA announces its
decision to renew an exemption for one
individual from the requirement in the
Federal Motor Carrier Safety
Regulations (FMCSRs) that interstate
commercial motor vehicle (CMV)
drivers have ‘‘no established medical
history or clinical diagnosis of epilepsy
or any other condition which is likely
to cause loss of consciousness or any
loss of ability to control a CMV.’’ The
exemption enables this individual who
has had one or more seizures and is
taking anti-seizure medication to
continue to operate CMVs in interstate
commerce.
DATES: The exemption was applicable
on October 22, 2019. The exemption
expires on October 22, 2021.
FOR FURTHER INFORMATION CONTACT: Ms.
Christine A. Hydock, Chief, Medical
SUMMARY:
PO 00000
Frm 00085
Fmt 4703
Sfmt 4703
Programs Division, (202) 366–4001,
fmcsamedical@dot.gov, FMCSA,
Department of Transportation, 1200
New Jersey Avenue SE, Room W64–224,
Washington, DC 20590–0001. Office
hours are from 8:30 a.m. to 5 p.m., ET,
Monday through Friday, except Federal
holidays. If you have questions
regarding viewing or submitting
material to the docket, contact Docket
Operations, (202) 366–9826.
SUPPLEMENTARY INFORMATION:
I. Public Participation
A. Viewing Documents and Comments
To view comments, as well as any
documents mentioned in this notice as
being available in the docket, go to or
https://www.regulations.gov/
docket?D=FMCSA-2015-0118 and
choose the document to review. If you
do not have access to the internet, you
may view the docket online by visiting
Docket Operations in Room W12–140
on the ground floor of the DOT West
Building, 1200 New Jersey Avenue SE,
Washington, DC 20590, between 9 a.m.
and 5 p.m., ET, Monday through Friday,
except Federal holidays.
B. Privacy Act
In accordance with 5 U.S.C. 553(c),
DOT solicits comments from the public
to better inform its rulemaking process.
DOT posts these comments, without
edit, including any personal information
the commenter provides, to
www.regulations.gov, as described in
the system of records notice (DOT/ALL–
14 FDMS), which can be reviewed at
www.transportation.gov/privacy.
II. Background
On December 4, 2019, FMCSA
published a notice announcing its
decision to renew an exemption for one
individual from the epilepsy and
seizure disorders prohibition in 49 CFR
391.41(b)(8) to operate a CMV in
interstate commerce and requested
comments from the public (84 FR
66454). The public comment period
ended on January 3, 2020, and no
comments were received.
FMCSA has evaluated the eligibility
of this applicant and determined that
renewing the exemption would achieve
a level of safety equivalent to, or greater
than, the level that would be achieved
by complying with § 391.41(b)(8).
The physical qualification standard
for drivers regarding epilepsy found in
§ 391.41(b)(8) states that a person is
physically qualified to drive a CMV if
that person has no established medical
history or clinical diagnosis of epilepsy
or any other condition which is likely
E:\FR\FM\29JAN1.SGM
29JAN1
Federal Register / Vol. 85, No. 19 / Wednesday, January 29, 2020 / Notices
to cause the loss of consciousness or any
loss of ability to control a CMV.
In addition to the regulations, FMCSA
has published advisory criteria 1 to
assist medical examiners in determining
whether drivers with certain medical
conditions are qualified to operate a
CMV in interstate commerce.
III. Discussion of Comments
Federal Motor Carrier Safety
Administration
[Docket No. FMCSA–2019–0167]
Qualification of Drivers; Exemption
Applications; Implantable Cardioverter
Defibrillator (ICD)
FMCSA received no comments in this
proceeding.
Federal Motor Carrier Safety
Administration (FMCSA), DOT.
ACTION: Notice of denials.
IV. Conclusion
SUMMARY:
AGENCY:
Based on its evaluation of the one
renewal exemption application, FMCSA
announces its decision to exempt the
following driver from the epilepsy and
seizure disorders prohibition in
§ 391.41(b)(8).
As of October 22, 2019, and in
accordance with 49 U.S.C. 31136(e) and
31315(b), Anthony Martens (SD) has
satisfied the renewal conditions for
obtaining an exemption from the
epilepsy and seizure disorders
prohibition in the FMCSRs for interstate
CMV drivers (84 FR 66454).
This driver was included in docket
number FMCSA–2015–0118. The
exemption is applicable as of October
22, 2019, and will expire on October 22,
2021.
In accordance with 49 U.S.C.
31315(b), the exemption will be valid
for 2 years from the effective date unless
revoked earlier by FMCSA. The
exemption will be revoked if the
following occurs: (1) The person fails to
comply with the terms and conditions
of the exemption; (2) the exemption has
resulted in a lower level of safety than
was maintained prior to being granted;
or (3) continuation of the exemption
would not be consistent with the goals
and objectives of 49 U.S.C. 31136(e) and
31315(b).
Issued on: January 23, 2020.
Larry W. Minor,
Associate Administrator for Policy.
[FR Doc. 2020–01551 Filed 1–28–20; 8:45 am]
BILLING CODE 4910–EX–P
lotter on DSKBCFDHB2PROD with NOTICES
DEPARTMENT OF TRANSPORTATION
1 These criteria may be found in APPENDIX A TO
PART 391—MEDICAL ADVISORY CRITERIA,
section H. Epilepsy: § 391.41(b)(8), paragraphs 3, 4,
and 5, which is available on the internet at https://
www.gpo.gov/fdsys/pkg/CFR-2015-title49-vol5/pdf/
CFR-2015-title49-vol5-part391-appA.pdf.
VerDate Sep<11>2014
17:27 Jan 28, 2020
Jkt 250001
FMCSA announces its
decision to deny applications from four
individuals treated with Implantable
Cardioverter Defibrillators (ICDs) who
requested an exemption from the
Federal Motor Carrier Safety
Regulations (FMCSRs) prohibiting
operation of a commercial motor vehicle
(CMV) in interstate commerce by
persons with a current clinical diagnosis
of myocardial infarction, angina
pectoris, coronary insufficiency,
thrombosis, or any other cardiovascular
disease of a variety known to be
accompanied by syncope (transient loss
of consciousness), dyspnea (shortness of
breath), collapse, or congestive heart
failure.
Ms.
Christine A. Hydock, Chief, Medical
Programs Division, (202) 366–4001,
fmcsamedical@dot.gov, FMCSA,
Department of Transportation, 1200
New Jersey Avenue SE, Room W64–224,
Washington, DC 20590–0001. Office
hours are from 8:30 a.m. to 5 p.m., ET,
Monday through Friday, except Federal
holidays. If you have questions
regarding viewing materials in the
docket, contact Docket Operations, (202)
366–9826.
SUPPLEMENTARY INFORMATION:
FOR FURTHER INFORMATION CONTACT:
I. Public Participation
A. Viewing Documents and Comments
To view comments, as well as any
documents mentioned in this notice as
being available in the docket, go to
https://www.regulations.gov/
docket?D=FMCSA-2019-0167 and
choose the document to review. If you
do not have access to the internet, you
may view the docket online by visiting
Docket Operations in Room W12–140
on the ground floor of the DOT West
Building, 1200 New Jersey Avenue SE,
Washington, DC 20590, between 9 a.m.
and 5 p.m., ET, Monday through Friday,
except Federal holidays.
B. Privacy Act
In accordance with 5 U.S.C. 553(c),
DOT solicits comments from the public
to better inform its rulemaking process.
PO 00000
Frm 00086
Fmt 4703
Sfmt 4703
5275
DOT posts these comments, without
edit, including any personal information
the commenter provides, to
www.regulations.gov, as described in
the system of records notice (DOT/ALL–
14 FDMS), which can be reviewed at
www.transportation.dot.gov/privacy.
II. Background
On October 1, 2019 FMCSA published
a Federal Register notice (84 FR 52163)
announcing receipt of applications from
four individuals treated with ICDs and
requesting comments from the public.
These four individuals requested an
exemption from 49 CFR 391.41(b)(4)
that prohibits operation of a CMV in
interstate commerce by persons with a
current clinical diagnosis of myocardial
infarction, angina pectoris, coronary
insufficiency, thrombosis, or any other
cardiovascular disease of a variety
known to be accompanied by syncope,
dyspnea, collapse, or congestive heart
failure. The public comment period
closed on October 31, 2019 and three
comments were received.
FMCSA has evaluated the eligibility
of these applicants and concluded that
granting these exemptions would not
provide a level of safety that would be
equivalent to, or greater than, the level
of safety that would be obtained by
complying with § 391.41(b)(4). A
summary of each applicant’s medical
history related to their ICD exemption
request was discussed in the October 1,
2019, Federal Register notice and will
not be repeated here.
The Agency’s decision regarding these
exemption applications is based on
information from the cardiovascular
Medical Advisory Criteria, an April
2007 evidence report titled
‘‘Cardiovascular Disease and
Commercial Motor Vehicle Driver
Safety,’’ 1 and further supported in a
December 2014 focused research report
titled ‘‘Implantable Cardioverter
Defibrillators and the Impact of a Shock
in a Patient When Deployed.’’ Copies of
these reports are included in the docket.
FMCSA has published advisory
criteria to assist medical examiners in
determining whether drivers with
certain medical conditions are qualified
to operate a CMV in interstate
commerce.2 The advisory criteria for
§ 391.41(b)(4) indicates that coronary
artery bypass surgery and pacemaker
1 The April 2007 Evidence report is available on
the internet at https://rosap.ntl.bts.gov/view/dot/
16462.
2 These criteria may be found in 49 CFR part 391,
APPENDIX A TO PART 391—MEDICAL
ADVISORY CRITERIA, section D. Cardiovascular:
§ 391.41(b)(4), paragraph 4, which is available on
the internet at https://www.gpo.gov/fdsys/pkg/CFR2015-title49-vol5/pdf/CFR-2015-title49-vol5part391-appA.pdf.
E:\FR\FM\29JAN1.SGM
29JAN1
Agencies
[Federal Register Volume 85, Number 19 (Wednesday, January 29, 2020)]
[Notices]
[Pages 5274-5275]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-01551]
-----------------------------------------------------------------------
DEPARTMENT OF TRANSPORTATION
Federal Motor Carrier Safety Administration
[Docket No. FMCSA-2015-0118]
Qualification of Drivers; Exemption Applications; Epilepsy and
Seizure Disorders
AGENCY: Federal Motor Carrier Safety Administration (FMCSA), DOT.
ACTION: Notice of final disposition.
-----------------------------------------------------------------------
SUMMARY: FMCSA announces its decision to renew an exemption for one
individual from the requirement in the Federal Motor Carrier Safety
Regulations (FMCSRs) that interstate commercial motor vehicle (CMV)
drivers have ``no established medical history or clinical diagnosis of
epilepsy or any other condition which is likely to cause loss of
consciousness or any loss of ability to control a CMV.'' The exemption
enables this individual who has had one or more seizures and is taking
anti-seizure medication to continue to operate CMVs in interstate
commerce.
DATES: The exemption was applicable on October 22, 2019. The exemption
expires on October 22, 2021.
FOR FURTHER INFORMATION CONTACT: Ms. Christine A. Hydock, Chief,
Medical Programs Division, (202) 366-4001, [email protected]t.gov, FMCSA,
Department of Transportation, 1200 New Jersey Avenue SE, Room W64-224,
Washington, DC 20590-0001. Office hours are from 8:30 a.m. to 5 p.m.,
ET, Monday through Friday, except Federal holidays. If you have
questions regarding viewing or submitting material to the docket,
contact Docket Operations, (202) 366-9826.
SUPPLEMENTARY INFORMATION:
I. Public Participation
A. Viewing Documents and Comments
To view comments, as well as any documents mentioned in this notice
as being available in the docket, go to or https://www.regulations.gov/docket?D=FMCSA-2015-0118 and choose the document to review. If you do
not have access to the internet, you may view the docket online by
visiting Docket Operations in Room W12-140 on the ground floor of the
DOT West Building, 1200 New Jersey Avenue SE, Washington, DC 20590,
between 9 a.m. and 5 p.m., ET, Monday through Friday, except Federal
holidays.
B. Privacy Act
In accordance with 5 U.S.C. 553(c), DOT solicits comments from the
public to better inform its rulemaking process. DOT posts these
comments, without edit, including any personal information the
commenter provides, to www.regulations.gov, as described in the system
of records notice (DOT/ALL-14 FDMS), which can be reviewed at
www.transportation.gov/privacy.
II. Background
On December 4, 2019, FMCSA published a notice announcing its
decision to renew an exemption for one individual from the epilepsy and
seizure disorders prohibition in 49 CFR 391.41(b)(8) to operate a CMV
in interstate commerce and requested comments from the public (84 FR
66454). The public comment period ended on January 3, 2020, and no
comments were received.
FMCSA has evaluated the eligibility of this applicant and
determined that renewing the exemption would achieve a level of safety
equivalent to, or greater than, the level that would be achieved by
complying with Sec. 391.41(b)(8).
The physical qualification standard for drivers regarding epilepsy
found in Sec. 391.41(b)(8) states that a person is physically
qualified to drive a CMV if that person has no established medical
history or clinical diagnosis of epilepsy or any other condition which
is likely
[[Page 5275]]
to cause the loss of consciousness or any loss of ability to control a
CMV.
In addition to the regulations, FMCSA has published advisory
criteria \1\ to assist medical examiners in determining whether drivers
with certain medical conditions are qualified to operate a CMV in
interstate commerce.
---------------------------------------------------------------------------
\1\ These criteria may be found in APPENDIX A TO PART 391--
MEDICAL ADVISORY CRITERIA, section H. Epilepsy: Sec. 391.41(b)(8),
paragraphs 3, 4, and 5, which is available on the internet at
https://www.gpo.gov/fdsys/pkg/CFR-2015-title49-vol5/pdf/CFR-2015-title49-vol5-part391-appA.pdf.
---------------------------------------------------------------------------
III. Discussion of Comments
FMCSA received no comments in this proceeding.
IV. Conclusion
Based on its evaluation of the one renewal exemption application,
FMCSA announces its decision to exempt the following driver from the
epilepsy and seizure disorders prohibition in Sec. 391.41(b)(8).
As of October 22, 2019, and in accordance with 49 U.S.C. 31136(e)
and 31315(b), Anthony Martens (SD) has satisfied the renewal conditions
for obtaining an exemption from the epilepsy and seizure disorders
prohibition in the FMCSRs for interstate CMV drivers (84 FR 66454).
This driver was included in docket number FMCSA-2015-0118. The
exemption is applicable as of October 22, 2019, and will expire on
October 22, 2021.
In accordance with 49 U.S.C. 31315(b), the exemption will be valid
for 2 years from the effective date unless revoked earlier by FMCSA.
The exemption will be revoked if the following occurs: (1) The person
fails to comply with the terms and conditions of the exemption; (2) the
exemption has resulted in a lower level of safety than was maintained
prior to being granted; or (3) continuation of the exemption would not
be consistent with the goals and objectives of 49 U.S.C. 31136(e) and
31315(b).
Issued on: January 23, 2020.
Larry W. Minor,
Associate Administrator for Policy.
[FR Doc. 2020-01551 Filed 1-28-20; 8:45 am]
BILLING CODE 4910-EX-P